Posted by Michael Wonder on 24 Nov 2025
Merck takes patient-directed approach to bring innovation to the treatment of rare neuromuscular disorder, generalised myasthenia gravis
24 November 2025 - Merck today announced the FDA has granted fast track designation for cladribine capsules for the treatment of generalised myasthenia gravis.
In June 2023, the FDA granted orphan drug designation for cladribine capsules for the treatment of generalised myasthenia gravis. In addition, the Company is actively collaborating with patient organisations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of generalszed myasthenia gravis.
